Exenatide once weekly slows gastric emptying of solids and liquids in healthy, overweight people at steady‐state concentrations
The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
Aims: To evaluate the effects of 8 weeks’ administration of exenatide (EXE) once weekly on gastric emptying of solids and liquids (using the “gold standard” technique, scintigraphy), glucose absorption and postprandial glycaemia in healthy people. Material and methods: A total of 32 healthy participants were randomized to receive either EXE once weekly (2 mg/wk subcutaneously; six men, 10 women, mean age 59.9 ± 0.9 years, mean body mass index [BMI] 29.6 ± 0.6 kg/m 2 ) or matching placebo (PBO; six men, 10 women, mean age 60.6 ± 1.2 years, mean BMI 29.5 ± 1.0 kg/m 2 ) for 8 weeks. Gastric emptying, nausea (visual analogue scale), and plasma glucose, insulin, C‐peptide and glucagon were measured for 120 min after a solid/liquid meal, comprising 100 g ground beef (radiolabelled with 20 MBq 99m Tc‐sulphur colloid) and 150 mL 10% glucose (radiolabelled with 7 MBq 67 Ga‐EDTA), and containing 5 g 3‐O‐methyl‐glucose (3‐OMG) as a marker of glucose absorption, at baseline and after 8 weeks’ treatment. Results: The study treatments were well tolerated. Scores for nausea were consistently low, with no difference between the EXE once weekly and PBO groups. EXE once weekly slowed gastric emptying of solids (area under the curve [AUC] 0–120min : P < 0.05) and liquids (AUC 0–120min : P = 0.01) substantially, and attenuated glucose absorption (3‐OMG incremental AUC [iAUC] 0–30min : P = 0.001) and the postprandial rise in plasma glucose (iAUC 0–30min : P = 0.008). Plasma glucagon at 2 h was reduced by EXE once weekly ( P = 0.001). The magnitude of the reduction in plasma glucose at t = 30 min from baseline to 8 weeks with EXE once weekly was related inversely to the 50% emptying time of the glucose drink ( r = −0.55, P = 0.03). Conclusions: In healthy participants, 8 weeks’ administration of the “long‐acting” glucagon‐like peptide‐1 receptor agonist EXE, slowed gastric emptying of solids and liquids substantially, with consequent reductions in glucose absorption and postprandial glycaemia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Monnier, L., Lapinski, H., & Colette, C. (2003) · Diabetes Care · doi:10.2337/diacare.26.3.881 · Cited by 1,461
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
Meier, J. J. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.140 · Cited by 1,311 · cited 12×
“Glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) are used widely, and increasingly, in the management of type 2 diabetes(1,2) and, on the basis of their plasma half-life, may be classified as “short-” (eg, exenatide [EXE] twice daily, lixisenatide) or “long-” (eg, EXE once weekly, liraglutide, dulaglutide, sema…”
BackgroundResultInfluentialNauck, M. A., Kleine, N., �rskov, C., Holst, J. J., Willms, B., & Creutzfeldt, W. (1993) · Diabetologia · doi:10.1007/bf00401145 · Cited by 1,092
Drucker, D. J., Buse, J. B., Taylor, K., Kendall, D. M., Trautmann, M., Zhuang, D., & Porter, L. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61206-4 · Cited by 1,070 · cited 2×
“Comparative studies of EXE once weekly with EXE twice daily in type 2 diabetes indicate that EXE once weekly is associated with greater reductions in fasting/preprandial glucose, while EXE twice daily leads to greater reductions in postprandial glucose.(1,29) This is also the case when liraglutide is compared to lixis…”
BackgroundNauck, M. A., Meier, J. J., Cavender, M. A., Abd El Aziz, M., & Drucker, D. J. (2017) · Circulation · doi:10.1161/circulationaha.117.028136 · Cited by 582
Relationship between oral glucose tolerance and gastric emptying in normal healthy subjects
Horowitz, M., Edelbroek, M. A. L., Wishart, J. M., & Straathof, J. W. (1993) · Diabetologia · doi:10.1007/bf00400362 · Cited by 469 · cited 1×
“ponent), consistent with previous studies establishing gastric emptying as a major determinant of early postprandial glycaemia.(11,12) This is despite the predictably modest glycaemic response in healthy participants.”
ResultSelf-citationSchvarcz, E., Palmer, M., Aman, J., Horowitz, M., Stridsberg, M., & Berne, C. (1997) · Gastroenterology · doi:10.1016/s0016-5085(97)70080-5 · Cited by 416
Self-citationNauck, M. A., Kemmeries, G., Holst, J. J., & Meier, J. J. (2011) · Diabetes · doi:10.2337/db10-0474 · Cited by 392 · cited 2×
“hence, have a dominant postprandial effect, while long-acting GLP-1RAs may have minimal or no effect on gastric emptying with sustained administration as a result of tachyphylaxis, so that their glucose-lowering is preferentially preprandial, reflecting stimulation of insulin and suppression of glucagon.(21,24) This c…”
BackgroundMeier, J. J., Gallwitz, B., Salmen, S., Goetze, O., Holst, J. J., Schmidt, W. E., & Nauck, M. A. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030049 · Cited by 369
Gastric emptying and glycaemia in health and diabetes mellitus
Phillips, L. K., Deane, A. M., Jones, K. L., Rayner, C. K., & Horowitz, M. (2015) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2014.202 · Cited by 273 · cited 2×
“Their current use is essentially empirical, rather than “personalized” as is increasingly recommended.(1,2) A number of long-acting GLP-1RAs have been shown to reduce cardiovascular risk.”
BackgroundSelf-citationMeier, J. J., Rosenstock, J., Hincelin-Méry, A., Roy-Duval, C., Delfolie, A., Coester, H.-V., Menge, B. A., Forst, T., & Kapitza, C. (2015) · Diabetes Care · doi:10.2337/dc14-1984 · Cited by 262
Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes
Linnebjerg, H., Park, S., Kothare, P. A., Trautmann, M. E., Mace, K., Fineman, M., Wilding, I., Nauck, M., & Horowitz, M. (2008) · Regulatory Peptides · doi:10.1016/j.regpep.2008.07.003 · Cited by 261
Self-citationDelgado-Aros, S., Kim, D.-Y., Burton, D. D., Thomforde, G. M., Stephens, D., Brinkmann, B. H., Vella, A., & Camilleri, M. (2002) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.2002.282.3.g424 · Cited by 235 · cited 1×
“This concept was modified by the recognition that gastric emptying, which exhibits a substantial inter-individual variation in healthy people and is frequently disordered in those with type 2 diabetes,(9,10) is a major determinant of the glycaemic response to oral glucose, and carbohydrate-containing meals, in healthy…”
BackgroundHalawi, H., Khemani, D., Eckert, D., O'Neill, J., Kadouh, H., Grothe, K., Clark, M. M., Burton, D. D., Vella, A., Acosta, A., et al. (2017) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(17)30285-6 · Cited by 224 · cited 6×
“Evaluation of the effects of a drug on gastric emptying in type 2 diabetes is complicated by the potentially confounding effects of both acute hyperglycaemia, which slows gastric emptying,30 autonomic neuropathy10 and the greater variability of gastric emptying.31 These factors may have contributed to an underestimate…”
BackgroundInfluentialImpact of chronic gastrointestinal symptoms in diabetes mellitus on health-related quality of life
Talley, N. J., Young, L., Bytzer, P., Hammer, J., Leemon, M., Jones, M., & Horowitz, M. (2001) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2001.03350.x · Cited by 220 · cited 1×
“Type 2 diabetes is associated with an increased prevalence of gastrointestinal symptoms which affect quality of life adversely.(43) Gastrointestinal adverse effects, particularly nausea, are associated with EXE once weekly and other GLP-1RAs and may lead to discontinuation of therapy.”
BackgroundSelf-citationUmapathysivam, M. M., Lee, M. Y., Jones, K. L., Annink, C. E., Cousins, C. E., Trahair, L. G., Rayner, C. K., Chapman, M. J., Nauck, M. A., Horowitz, M., et al. (2014) · Diabetes · doi:10.2337/db13-0893 · Cited by 193 · cited 1×
“tion in the two studies with regard to the tachyphylaxis relating to the slowing of gastric emptying by exogenous GLP-1, is that, after continuous administration, GLP-1 still slowed gastric emptying substantially; that is, its effects were not abolished.(20,21) It is clear that short-acting GLP-1RAs slow gastric empty…”
BackgroundSelf-citationHorowitz, M., Flint, A., Jones, K. L., Hindsberger, C., Rasmussen, M. F., Kapitza, C., Doran, S., Jax, T., Zdravkovic, M., & Chapman, I. M. (2012) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2012.02.016 · Cited by 179 · cited 7×
“Evaluation of the effects of a drug on gastric emptying in type 2 diabetes is complicated by the potentially confounding effects of both acute hyperglycaemia, which slows gastric emptying,30 autonomic neuropathy10 and the greater variability of gastric emptying.31 These factors may have contributed to an underestimate…”
BackgroundMethodSelf-citationFlint, A., Kapitza, C., Hindsberger, C., & Zdravkovic, M. (2011) · Advances in Therapy · doi:10.1007/s12325-010-0110-x · Cited by 91
Jones, K. L., Rigda, R. S., Buttfield, M. D. M., Hatzinikolas, S., Pham, H. T., Marathe, C. S., Wu, T., Lange, K., Trahair, L. G., Rayner, C. K., et al. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13633 · Cited by 66
Self-citation
Cited by
Effects of GLP-1 and Its Analogs on Gastric Physiology in Diabetes Mellitus and Obesity
Maselli, D. B., & Camilleri, M. (2020) · Advances in Experimental Medicine and Biology · doi:10.1007/5584_2020_496 · Cited by 248
Gastrointestinal effects of GLP-1 receptor agonists: mechanisms, management, and future directions
Jalleh, R. J., Rayner, C. K., Hausken, T., Jones, K. L., Camilleri, M., & Horowitz, M. (2024) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(24)00188-2 · Cited by 144
Self-citationvan Zuylen, M. L., Siegelaar, S. E., Plummer, M. P., Deane, A. M., Hermanides, J., & Hulst, A. H. (2024) · British Journal of Anaesthesia · doi:10.1016/j.bja.2024.01.001 · Cited by 132
Oprea, A. D., Ostapenko, L. J., Sweitzer, B., Selzer, A., Irizarry-Alvarado, J. M., Hurtado Andrade, M. D., Mendez, C. E., Kelley, K. D., Stewart, E., Fernandez Robles, C. R., et al. (2025) · British Journal of Anaesthesia · doi:10.1016/j.bja.2025.04.001 · Cited by 104
Jalleh, R. J., Jones, K. L., Rayner, C. K., Marathe, C. S., Wu, T., & Horowitz, M. (2022) · Diabetologia · doi:10.1007/s00125-022-05796-1 · Cited by 87
“exenatide once weekly [QW], liraglutide, dulaglutide, semaglutide [subcutaneous and oral] and tirzepatide [a dual GIP/GLP-1 receptor agonist]) on gastric emptying have, for the main part, been evaluated with the suboptimal paracetamol test [17, 39–43], rather than a more accurate technique [44].”
BackgroundMethodInfluentialSelf-citation
Metadata
- Authors
- Jones, K. L., Huynh, L. Q., Hatzinikolas, S., Rigda, R. S., Phillips, L. K., Pham, H. T., Marathe, C. S., Wu, T., Malbert, C. H., Stevens, J. E., Lange, K., Rayner, C. K., & Horowitz, M.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2020-01-28
- Volume
- 22
- Issue
- 5
- Pages
- 788-797
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2998516536
- Cited by
- 76
- References
- 19
- FWCI
- 5.41
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.